Articles related to GENITOURINARY CANCER

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.

A multi-variate analysis published in Cancer Medicine, which includes a population of more than 150,000 individuals, suggests that prior cannabis use was associated with a reduced risk of renal cell carcinoma and bladder cancer in women and prostate cancer in men. A potentially conflicting finding was increased risk of some cancers in current cannabis users.

In this case, the second in a three-part series, a man was diagnosed with prostate cancer based on a prostate-specific antigen (PSA) level of 6.5 ng/mL. The initial diagnosis was stage 3 disease (T3, N0, M0), with a Gleason score of 3+4=7. The rationale for the treatment decisions is explained, along with the trials (ARAMIS, SPARTAN, PROSPER) that influenced the decisions.

Some physicians believe that Gleason 6 should be reclassified as something other than cancer, which could be a valid argument because Gleason 6 isn’t going to cause any harm and therefore can be safely observed. This commentary provides arguments as to why that reclassification idea is a flawed concept.

The study was comprised of 17,913 men with a median age of 64 years with pT2-4N1M0 prostate cancer (PC) consecutively treated between 1995 and 2017, with postradical prostatectomy (RP) and pelvic lymph node (LN) assessment. The patients were then followed for possible treatment with adjuvant radiation therapy (aRT) or early salvage radiation therapy (sRT). It was determined that men with pN1 PC and 4 or more as compared with 1-3 positive pelvic LNs appear to benefit the most from the use of aRT.

Dr. Christopher J. Hoimes, Associate Professor of Medicine-GU Oncology at Duke University, presents data on the KEYNOTE-045 Phase 3 Trial, which demonstrated that patients treated with KEYTRUDA (pembrolizumab) had a 27% reduction in risk of death compared to patients treated with chemotherapy.